Marker vaccine strategies and candidate CSFV marker vaccines (Q36578325)

15 August 2017

1 reference

title

Marker vaccine strategies and candidate CSFV marker vaccines (English)

1 reference

15 August 2017

1 reference

Xiao-Nan Dong

1

1 reference

PubMed ID

16934915

15 August 2017

Ying-Hua Chen

series ordinal

2

1 reference

PubMed ID

16934915

15 August 2017

language of work or name

English

0 references

publication date

7 August 2006

1 reference

15 August 2017

1 reference

15 August 2017

25

1 reference

15 August 2017

2

1 reference

15 August 2017

205-230

1 reference

Introduction to classical swine fever: virus, disease and control policy

15 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Localization of pestiviral envelope proteins E(rns) and E2 at the cell surface and on isolated particles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Inhibition of pestivirus infection in cell culture by envelope proteins E(rns) and E2 of classical swine fever virus: E(rns) and E2 interact with different receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

RNA-stimulated NTPase activity associated with the p80 protein of the pestivirus bovine viral diarrhea virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Identification of classical swine fever virus protein E2 as a target for cytotoxic T cells by using mRNA-transfected antigen-presenting cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The E2 glycoprotein of classical swine fever virus is a virulence determinant in swine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Identification of a structural glycoprotein of an RNA virus as a ribonuclease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Determinants of virulence of classical swine fever virus strain Brescia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Propagation of hog cholera virus in rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Serial passage of hog cholera virus in rabbits.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccinology of classical swine fever: from lab to field

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

In vivo effect on pig chromosomes of high dosage vaccine against classic swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Pig chromosome aberrations after vaccination against classical swine fever in field trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever: the European experience and a guide for infected areas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The 1997-1998 epidemic of classical swine fever in the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

A model to estimate the financial consequences of classical swine fever outbreaks: principles and outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Marker vaccines, virus protein-specific antibody assays and the control of Aujeszky's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The use of marker vaccines in eradication of herpesviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Simulated effect of pig-population density on epidemic size and choice of control strategy for classical swine fever epidemics in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Spatial and stochastic simulation to compare two emergency-vaccination strategies with a marker vaccine in the 1997/1998 Dutch Classical Swine Fever epidemic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Diva vaccines that reduce virus transmission

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Blending of a conventional Mycoplasma hyopneumoniae vaccine with a positive marker: tracking of immunised pigs by peptide-specific antibodies raised to the marker component.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccinia virus: a versatile tool for molecular biologists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccinia virus vectors: new strategies for producing recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccinia virus: a suitable vehicle for recombinant vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

NYVAC: a highly attenuated strain of vaccinia virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

A highly attenuated host range-restricted vaccinia virus strain, NYVAC, encoding the prM, E, and NS1 genes of Japanese encephalitis virus prevents JEV viremia in swine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccination of pigs against pseudorabies with highly attenuated vaccinia (NYVAC) recombinant viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Recombinant fowlpox virus inducing protective immunity in non-avian species

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Potential use of non-replicating vectors as recombinant vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Induction of humoral and cellular immune responses in mice by a recombinant fowlpox virus expressing the E2 protein of bovine viral diarrhea virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Construction of recombinant swinepox viruses and expression of the classical swine fever virus E2 protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Potential viral vectors for the stimulation of mucosal antibody responses against enteric viral antigens in pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Generation of recombinant parapoxviruses: non-essential genes suitable for insertion and expression of foreign genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Pseudorabies virus as a live virus vector for expression of foreign genes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Inactivation of the thymidine kinase gene of a gI deletion mutant of pseudorabies virus generates a safe but still highly immunogenic vaccine strain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Comparison of the protective efficacy of recombinant pseudorabies viruses against pseudorabies and classical swine fever in pigs; influence of different promoters on gene expression and on protection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Virulence and pathogenesis of non-virulent and virulent strains of pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Biologically safe, non-transmissible pseudorabies virus vector vaccine protects pigs against both Aujeszky's disease and classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Serological and pathogenicity studies with some unclassified porcine adenoviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Isolation of porcine adenovirus from the respiratory tract of pigs in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Porcine adenovirus as a delivery system for swine vaccines and immunotherapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Development of porcine adenovirus-3 as an expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Porcine adenovirus-3 as a helper-dependent expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Vaccination with a single dose of a recombinant porcine adenovirus expressing the classical swine fever virus gp55 (E2) gene protects pigs against classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Construction and characterization of recombinant porcine adenovirus serotype 5 expressing the transmissible gastroenteritis virus spike gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

A recombinant E1-deleted porcine adenovirus-3 as an expression vector

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Oral and sub-cutaneous vaccination of commercial pigs with a recombinant porcine adenovirus expressing the classical swine fever virus gp55 gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Protection of pigs against ‘in contact’ challenge with classical swine fever following oral or subcutaneous vaccination with a recombinant porcine adenovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Genetic and antigenic characterization of novel pestivirus genotypes: implications for classification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

An avirulent chimeric Pestivirus with altered cell tropism protects pigs against lethal infection with classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The envelope glycoprotein E2 is a determinant of cell culture tropism in ruminant pestiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Mutations in the 5' nontranslated region of bovine viral diarrhea virus result in altered growth characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Bovine viral diarrhea virus with deletions in the 5'-nontranslated region: reduction of replication in calves and induction of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Antigenic differentiation of pestivirus strains with monoclonal antibodies against hog cholera virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The development of an international reference panel of monoclonal antibodies for the differentiation of hog cholera virus from other pestiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Differentiation of classical swine fever virus (CSFV) strains using monoclonal antibodies against structural glycoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Recombinant classical swine fever (CSF) viruses derived from the Chinese vaccine strain (C-strain) of CSF virus retain their avirulent and immunogenic characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever virus E(rns) deletion mutants: trans-complementation and potential use as nontransmissible, modified, live-attenuated marker vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Experimental non-transmissible marker vaccines for classical swine fever (CSF) by trans-complementation of E(rns) or E2 of CSFV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Topographical and functional mapping of epitopes on hog cholera virus with monoclonal antibodies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever virus replicon particles lacking the Erns gene: a potential marker vaccine for intradermal application.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Oronasal vaccination with classical swine fever virus (CSFV) replicon particles with either partial or complete deletion of the E2 gene induces partial protection against lethal challenge with highly virulent CSFV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Fine mapping of a C-terminal linear epitope highly conserved among the major envelope glycoprotein E2 (gp51 to gp54) of different pestiviruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Deletions of structural glycoprotein E2 of classical swine fever virus strain alfort/187 resolve a linear epitope of monoclonal antibody WH303 and the minimal N-terminal domain essential for binding immunoglobulin G antibodies of a pig hyperimmune s

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Chimeric classical swine fever viruses containing envelope protein E(RNS) or E2 of bovine viral diarrhoea virus protect pigs against challenge with CSFV and induce a distinguishable antibody response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Characterization of porcine and some ruminant pestiviruses by cross-neutralization.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Six antigenic groups within the genus pestivirus as identified by cross neutralization assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Mutation of E1 glycoprotein of classical swine fever virus affects viral virulence in swine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical Swine Fever Virus Interferes with Cellular Antiviral Defense: Evidence for a Novel Function of Npro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Loss of interferon regulatory factor 3 in cells infected with classical swine fever virus involves the N-terminal protease, Npro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

N(pro) of classical swine fever virus is an antagonist of double-stranded RNA-mediated apoptosis and IFN-alpha/beta induction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Role of double-stranded RNA and Npro of classical swine fever virus in the activation of monocyte-derived dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Attenuation of classical swine fever virus by deletion of the viral N(pro) gene

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Direct gene transfer into mouse muscle in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Genetic immunization is a simple method for eliciting an immune response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Heterologous protection against influenza by injection of DNA encoding a viral protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Protection of pigs against classical swine fever with DNA-delivered gp55.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

A prime-boost vaccination strategy using naked DNA followed by recombinant porcine adenovirus protects pigs from classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Porcine interleukin-3 enhances DNA vaccination against classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Immunomodulatory effect of plasmids co-expressing cytokines in classical swine fever virus subunit gp55/E2-DNA vaccination.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Co-administration of IL-2 enhances antigen-specific immune responses following vaccination with DNA encoding the glycoprotein E2 of bovine viral diarrhoea virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

DNA vaccination against bovine viral diarrhoea virus induces humoral and cellular responses in cattle with evidence for protection against viral challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Biological activity of immunostimulatory CpG DNA motifs in domestic animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

DNA vaccination using bacillus Calmette-Guerin-DNA as an adjuvant to enhance immune response to three kinds of swine diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

A DNA vaccine expressing the E2 protein of classical swine fever virus elicits T cell responses that can prime for rapid antibody production and confer total protection upon viral challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

DNA-mediated protection against classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Evaluation of genetic vaccine against classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Laboratory diagnosis, epizootiology, and efficacy of marker vaccines in classical swine fever: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Efficacy and stability of a subunit vaccine based on glycoprotein E2 of classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Development of a classical swine fever subunit marker vaccine and companion diagnostic test

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Duration of the protection of an E2 subunit marker vaccine against classical swine fever after a single vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Prevention of transplacental transmission of moderate-virulent classical swine fever virus after single or double vaccination with an E2 subunit vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Influence of maternal antibodies on efficacy of a subunit vaccine: transmission of classical swine fever virus between pigs vaccinated at 2 weeks of age.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Comparison of antibody values in sera of pigs vaccinated with a subunit or an attenuated vaccine against classical swine fever

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Safety and efficacy of a classical swine fever subunit vaccine in pregnant sows and their offspring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Efficacy of the classical swine fever (CSF) marker vaccine Porcilis Pesti in pregnant sows

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

An E2 sub-unit marker vaccine does not prevent horizontal or vertical transmission of classical swine fever virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Evaluation of the epidemiological importance of classical swine fever infected, E2 sub-unit marker vaccinated animals with RT-nPCR positive blood samples.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Efficacy of E2-sub-unit marker and C-strain vaccines in reducing horizontal transmission of classical swine fever virus in weaner pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

An experimental infection with classical swine fever in E2 sub-unit marker-vaccine vaccinated and in non-vaccinated pigs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever (CSF) marker vaccine. Trial I. Challenge studies in weaner pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever (CSF) marker vaccine. Trial II. Challenge study in pregnant sows.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever (CSF) marker vaccine. Trial III. Evaluation of discriminatory ELISAs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Epitope mapping of envelope glycoprotein E1 of hog cholera virus strain Brescia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever virus (CSFV) envelope glycoprotein E2 containing one structural antigenic unit protects pigs from lethal CSFV challenge

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Expression of the glycoprotein E2 of the classical swine fever virus in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Inclusion bodies from recombinant bacteria as a novel system for delivery of vaccine antigen by the oral route

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Classical swine fever virus-specific cytotoxic T lymphocytes and identification of a T cell epitope.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Identification of T-cell epitopes in the structural and non-structural proteins of classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Immunological properties of recombinant classical swine fever virus NS3 protein in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Efficacy and functionality of lipoprotein OprI from Pseudomonas aeruginosa as adjuvant for a subunit vaccine against classical swine fever.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Immunoprotective properties of transgenic plants expressing E2 glycoprotein from CSFV and cysteine protease from Fasciola hepatica.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Immunisation of volunteers with a synthetic peptide vaccine for enterotoxigenic Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Synthetic peptide vaccine confers protection against murine malaria

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Candidate peptide vaccine induced protection against classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Candidate multi-peptide-vaccine against classical swine fever virus induced potent immunity with serological marker

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Strategies for mapping neutralizing epitopes: one way and two sides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Workshop summary. Aluminum in vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Aluminum salts in vaccines--US perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Candidate peptide-vaccine induced potent protection against CSFV and identified a principal sequential neutralizing determinant on E2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Spying the neutralizing epitopes on E2 N-terminal by candidate epitope-vaccines against classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Candidate peptide-vaccines induced immunity against CSFV and identified sequential neutralizing determinants in antigenic domain A of glycoprotein E2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

The protective immune response induced by B cell epitope of classical swine fever virus glycoprotein E2.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Epitope mapping and affinity purification of monospecific antibodies by Escherichia coli cell surface display of gene-derived random peptide libraries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Identification of antigenic regions of the Erns protein for pig antibodies elicited during classical swine fever virus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Antibody responses of pigs to defined Erns fragments after infection with classical swine fever virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Characterization of epitopes for neutralizing monoclonal antibodies to classical swine fever virus E2 and Erns using phage-displayed random peptide library

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Quantification of the transmission of classical swine fever virus between herds during the 1997-1998 epidemic in The Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Structural proteins of hog cholera virus expressed by vaccinia virus: further characterization and induction of protective immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

Processing in the pestivirus E2-NS2 region: identification of proteins p7 and E2p7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Pestivirus NS3 (p80) protein possesses RNA helicase activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Pestivirus gene expression: Protein p80 of bovine viral diarrhea virus is a proteinase involved in polyprotein processing

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Pestivirus glycoprotein which induces neutralizing antibodies forms part of a disulfide-linked heterodimer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Mutations abrogating the RNase activity in glycoprotein E(rns) of the pestivirus classical swine fever virus lead to virus attenuation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Glycoprotein Erns of pestiviruses induces apoptosis in lymphocytes of several species

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Classical swine fever virus: independent induction of protective immunity by two structural glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Live attenuated pseudorabies virus expressing envelope glycoprotein E1 of hog cholera virus protects swine against both pseudorabies and hog cholera

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Glycoprotein D-negative pseudorabies virus can spread transneuronally via direct neuron-to-neuron transmission in its natural host, the pig, but not after additional inactivation of gE or gI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Processing of pestivirus polyprotein: cleavage site between autoprotease and nucleocapsid protein of classical swine fever virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

Classical swine fever virus leader proteinase Npro is not required for viral replication in cell culture

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2006.07.033

7 January 2021

10.1016/J.VACCINE.2006.07.033

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

16934915